Today: 3 February 2026
Subscribe
Browse Category

NASDAQ:RVPH News 10 December 2025 - 24 December 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals (RVPH) Stock Plunges After FDA Calls for Second Phase 3 Trial: News, Forecasts, and Analyst Takeaways on Dec. 24, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is in the spotlight on December 24, 2025 after a sharp selloff driven by a major regulatory development: the U.S. Food and Drug Administration recommended that Reviva run an additional Phase 3 trial for its lead schizophrenia candidate, brilaroxazine, before filing a New Drug Application (NDA). SEC Shares were trading around $0.32 after the…
24 December 2025
·····
Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is back on traders’ radar as a late‑stage CNS biotech preparing for a potential New Drug Application (NDA) in schizophrenia while its stock trades under $1 and analysts publish double‑ and even triple‑digit upside targets. As of mid‑session on December 10, 2025, RVPH is trading around $0.69 per share, up roughly 10% on the…
10 December 2025
···

Stock Market Today

  • BFF Bank Revises 2026 Targets and Outlines Factoring Portfolio De-risking
    February 3, 2026, 6:19 AM EST. BFF Bank S.p.A. announced actions to de-risk its factoring portfolio, aiming to strengthen financial stability before unveiling a new Strategic Plan. The bank also revised its performance targets for 2026, reflecting these adjustments. These moves precede potential securitization, which involves pooling financial assets to be sold as securities. BFF's strategy highlights its effort to manage credit risk and optimize capital structure. The update came alongside regulatory filings reported on Euronext Dublin, signaling a shift in the bank's growth trajectory and risk management approach.
Go toTop